RGEN logo

Repligen Corporation Stock Price

NasdaqGS:RGEN Community·US$8.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

RGEN Share Price Performance

US$148.73
12.14 (8.89%)
32.4% undervalued intrinsic discount
US$220.00
Fair Value
US$148.73
12.14 (8.89%)
32.4% undervalued intrinsic discount
US$220.00
Fair Value
Price US$148.73
AnalystHighTarget US$220.00
AnalystConsensusTarget US$179.72
AnalystLowTarget US$131.29

RGEN Community Narratives

AnalystHighTarget·Updated
Fair Value US$220 32.4% undervalued intrinsic discount

Next-Generation Biologics And Automation Will Elevate Bioprocessing Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$179.78 17.3% undervalued intrinsic discount

Expanding Dual Manufacturing And APAC Presence Will Drive Future Success

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AnalystLowTarget·Updated
Fair Value US$131.29 13.3% overvalued intrinsic discount

Inflation And Deglobalization Risks Will Curtail Progress As China Recovers

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Recent RGEN News & Updates

Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge

Oct 04
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge

Is Repligen (NASDAQ:RGEN) A Risky Investment?

Sep 01
Is Repligen (NASDAQ:RGEN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) P/S

Jul 29
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) P/S

Repligen: Long-Term Growth Gem Suffers Some Setbacks

Jun 08
User avatar

Biomanufacturing Expansion Will Create New Global Opportunities

Strong demand in biomanufacturing and effective market expansion are driving sustained revenue growth and improved margins for Repligen.

Repligen: Ongoing Bioprocessing Market Recovery

Mar 20

Repligen Corporation Key Details

US$674.0m

Revenue

US$330.3m

Cost of Revenue

US$343.7m

Gross Profit

US$357.5m

Other Expenses

-US$13.8m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.25
Gross Margin
50.99%
Net Profit Margin
-2.05%
Debt/Equity Ratio
25.9%

Repligen Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

1 Risk
2 Rewards

About RGEN

Founded
1981
Employees
1778
CEO
Olivier Loeillot
WebsiteView website
www.repligen.com

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 8.5%
  • 1 Year: 17.7%
  • Year to Date: 14.8%
Over the last 7 days, the market has risen 1.2%, driven by gains of 2.4% in the Information Technology sector. The market is up 18% over the last 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›